222 related articles for article (PubMed ID: 25265933)
41. Prospective study on the relationship between intensive bactericidal therapy and leprosy reactions.
Groenen G; Janssens L; Kayembe T; Nollet E; Coussens L; Pattyn SR
Int J Lepr Other Mycobact Dis; 1986 Jun; 54(2):236-44. PubMed ID: 3722962
[TBL] [Abstract][Full Text] [Related]
42. Reactional states in multibacillary Hansen disease patients during multidrug therapy.
Nery JA; Vieira LM; de Matos HJ; Gallo ME; Sarno EN
Rev Inst Med Trop Sao Paulo; 1998; 40(6):363-70. PubMed ID: 10436656
[TBL] [Abstract][Full Text] [Related]
43. Effectiveness of MDT in multibacillary leprosy.
Jesudasan K; Vijayakumaran P; Manimozhi N; Rao PS; Samuel P
Int J Lepr Other Mycobact Dis; 1996 Jun; 64(2):128-32. PubMed ID: 8690970
[TBL] [Abstract][Full Text] [Related]
44. Two multidrug fixed-dosage treatment regimens with multibacillary leprosy patients.
Gallo ME; Alvim MF; Nery JA; Albuquerque EC; Sarno EN
Indian J Lepr; 1996; 68(3):235-45. PubMed ID: 8889609
[TBL] [Abstract][Full Text] [Related]
45. Experience with WHO-recommended multidrug therapy (MDT) for multibacillary (MB) leprosy patients in the leprosy control program of the All Africa Leprosy and Rehabilitation Training Center in Ethiopia: appraisal of the recommended duration of MDT for MB patients.
Becx-Bleumink M
Int J Lepr Other Mycobact Dis; 1991 Dec; 59(4):558-68. PubMed ID: 1802938
[TBL] [Abstract][Full Text] [Related]
46. The efficacy of a four-week, ofloxacin-containing regimen compared with standard WHO-MDT in PB leprosy.
Balagon MF; Cellona RV; Abalos RM; Gelber RH; Saunderson PR
Lepr Rev; 2010 Mar; 81(1):27-33. PubMed ID: 20496567
[TBL] [Abstract][Full Text] [Related]
47. The effect of corticosteroids usage on bacterial killing, clearance and nerve damage in leprosy; part 3--Study of two comparable groups of 100 multibacillary (MB) patients each, treated with MDT + steroids vs. MDT alone, assessed at 6 months post-release from 12 months MDT.
Shetty VP; Khambati FA; Ghate SD; Capadia GD; Pai VV; Ganapati R
Lepr Rev; 2010 Mar; 81(1):41-58. PubMed ID: 20496569
[TBL] [Abstract][Full Text] [Related]
48. Experience with multidrug therapy in paucibacillary leprosy.
Bhate RD; Gupta CM; Chattopadhyay SP; Singh IP
Indian J Lepr; 1986; 58(2):244-50. PubMed ID: 3805797
[TBL] [Abstract][Full Text] [Related]
49. Fixed-duration multidrug therapy in multibacillary leprosy.
Li HY; Hu LF; Wu PW; Luo JS; Liu XM
Int J Lepr Other Mycobact Dis; 1997 Jun; 65(2):230-7. PubMed ID: 9251596
[TBL] [Abstract][Full Text] [Related]
50. Fixed-duration therapy (FDT) in multibacillary leprosy; efficacy and complications.
Vijayakumaran P; Jesudasan K; Manimozhi N
Int J Lepr Other Mycobact Dis; 1996 Jun; 64(2):123-7. PubMed ID: 8690969
[TBL] [Abstract][Full Text] [Related]
51. Parallel assessment of 24 monthly doses of rifampin, ofloxacin, and minocycline versus two years of World Health Organization multi-drug therapy for multi-bacillary leprosy.
Villahermosa LG; Fajardo TT; Abalos RM; Cellona RV; Balagon MV; Dela Cruz EC; Tan EV; Walsh GP; Walsh DS
Am J Trop Med Hyg; 2004 Feb; 70(2):197-200. PubMed ID: 14993633
[TBL] [Abstract][Full Text] [Related]
52. World Health Organization (WHO) antibiotic regimen against other regimens for the treatment of leprosy: a systematic review and meta-analysis.
Lazo-Porras M; Prutsky GJ; Barrionuevo P; Tapia JC; Ugarte-Gil C; Ponce OJ; Acuña-Villaorduña A; Domecq JP; De la Cruz-Luque C; Prokop LJ; Málaga G
BMC Infect Dis; 2020 Jan; 20(1):62. PubMed ID: 31959113
[TBL] [Abstract][Full Text] [Related]
53. MDT-MB therapy in paucibacillary leprosy: a clinicopathological assessment.
Prasad PV; Babu A; Kaviarasan PK; Viswanathan P; Tippoo R
Indian J Dermatol Venereol Leprol; 2005; 71(4):242-5. PubMed ID: 16394431
[TBL] [Abstract][Full Text] [Related]
54. Nasal mucosa and skin of smear-positive leprosy patients after 24 months of fixed duration MDT: histopathological and microbiological study.
Ebenezer GJ; Job A; Abraham S; Arunthathi S; Rao PS; Job CK
Int J Lepr Other Mycobact Dis; 1999 Sep; 67(3):292-7. PubMed ID: 10575409
[TBL] [Abstract][Full Text] [Related]
55. Is drug-resistant Mycobacterium leprae a real cause for concern?: First approach to molecular monitoring of multibacillary Colombian patients with and without previous leprosy treatment.
Guerrero MI; Colorado CL; Torres JF; León CI
Biomedica; 2014 Apr; 34 Suppl 1():137-47. PubMed ID: 24968045
[TBL] [Abstract][Full Text] [Related]
56. Multidrug therapy in leprosy.
Manglani PR; Arif MA
J Indian Med Assoc; 2006 Dec; 104(12):686-8. PubMed ID: 17474286
[TBL] [Abstract][Full Text] [Related]
57. Clinical analysis of multibacillary leprosy patients after 1-year fixed World Health Organization recommended multidrug therapy at Yangon General Hospital, Myanmar.
Kyaw K; Tsoh TM; Swe SY; Nagaoka Y; Takezaki S; Suzuki K; Ishii N
J Dermatol; 2008 May; 35(5):264-9. PubMed ID: 18477225
[TBL] [Abstract][Full Text] [Related]
58. Effect of rhuIFN-gamma treatment in multibacillary leprosy patients.
Sampaio EP; Malta AM; Sarno EN; Kaplan G
Int J Lepr Other Mycobact Dis; 1996 Sep; 64(3):268-73. PubMed ID: 8862260
[TBL] [Abstract][Full Text] [Related]
59. A young man with livid facial nodules and a loss of eyebrows.
Weberschock T; Göttig S
Lancet Infect Dis; 2013 Mar; 13(3):276. PubMed ID: 23427892
[No Abstract] [Full Text] [Related]
60. Polytherapy in multibacillary leprosy patients in Nepal.
Samuel NM; Samual S; Fairbairn T; Adiga RB
Singapore Med J; 1985 Apr; 26(2):203-6. PubMed ID: 4035403
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
